The Efficacy of a Probiotic for Functional Constipation (FC)
NCT ID: NCT06083311
Last Updated: 2025-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
55 participants
INTERVENTIONAL
2023-10-19
2024-12-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Probiotics Alleviate Functional Constipation in Adults
NCT06879587
Study for the Management of Chronic and Functional Constipation Through the Intake of Probiotics and Prebiotics
NCT06381193
Efficacy of Probiotic Against Functional Constipation
NCT06122558
Probiotic Intervention for Occasional Constipation
NCT06444139
Probiotics for Alleviating Functional Constipation in Adults
NCT06637397
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic
Participants in this arm will receive a daily dose of 3x10\^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
Probiotic
Participants in this arm will receive a daily dose of 3x10\^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
Placebo
Participants in this arm will receive an equivalent placebo for 28 days
Placebo
Participants in this arm will receive an equivalent placebo for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
Participants in this arm will receive a daily dose of 3x10\^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
Placebo
Participants in this arm will receive an equivalent placebo for 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body Mass Index (BMI) 18.5 - 30.0 kg/m2
3. Fulfilment of the Rome IV FC diagnostic criteria at V1 and V2
4. Self-reported average stool frequency of 3 or less bowel movements per week
5. Self-reported average stool consistency of type 1-4 on the Bristol Stool Form Scale
6. Cleveland Clinic Constipation Score \> 8 at V1
7. Readiness not to use any treatment/supplementation for complaints related to constipation (e.g. prokinetics, laxatives, enemas) during the study; exception: glycerol suppository and if it provides no benefit, participants are allowed to take oral laxatives (see section 0)
8. Readiness and ability to comply with and perform the procedures requested by the protocol
9. If receiving proton pump inhibitors (PPI), anticipated to continue PPI therapy for the duration of the trial
10. Readiness not to have any change in habitual diet or exercise patterns over the study period
11. Women:
* If sexually active, commitment to use contraception methods
* negative pregnancy testing (beta human chorionic gonadotropin test in urine) at V1
12. Generally, in the opinion of investigator, healthy individuals (e.g. no heart failure, no malignancy) Participation is based upon written informed consent by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.
Exclusion Criteria
2. Prior abdominal surgery in the past 3 years (except for laparoscopic appendectomy and cholecystectomy and other minor laparoscopic surgeries, as per investigator judgement, that are allowed)
3. Ongoing regular use of products that (in the investigator's opinion) are known to cause constipation or change gastric motility (e.g. iron; opioids; sucralfate; 5-HT3 antagonists (e.g. ondansetron); antacids with magnesium, calcium, or aluminum; anticholinergic agents; calcium supplements; trycyclic antidepressants; systemic steroids)
4. Any subjects with use of PPI within the last 8 weeks prior to Visit 1 (exception: continuous use for ≥ 8 week before Visit 1 is allowed)
5. Post-menopausal women, defined as \>12 months after the last menstrual bleeding and not using hormonal contraception
6. Women ≥ 50 years using hormonal contraception
7. ALARM features in the past 3 months prior to study (e.g. fever, unintentional weight loss ≥5 kg, blood in stool, vomiting) and moderate or severe anorectal problems (e.g. rectal bleeding, pelvic organ prolapse, anal fissures)
8. Previously diagnosed lactose intolerance, gluten intolerance, cow's milk allergy and/or soya-allergy
9. Known allergy or hypersensitivity to any ingredients of the investigational product
10. Consumption of biotic supplements (probiotics, prebiotics, synbiotics or post-biotics) within 2 weeks prior to Visit 1 and during the study
11. Regular consumption of fibre supplements and/or laxatives more than 1x a week
12. Use of laxatives within 48 hrs prior to Visit 1
13. Use of antibiotic within 4 weeks prior to Visit 1 and during the study
14. Ongoing alcohol, drug, or medication abuse
15. Participation in other clinical trials within 4 weeks prior to Visit 1 and during the study
16. Planning travel for \>1 week during the study duration
17. Anticipated major changes in diet or exercise during the study
18. Pregnant or lactating or planned to become pregnant during the study period
19. Smoking \> 5 cigarettes per week
20. An irregular diet, an abnormal sleep cycle, or other lifestyle abnormalities, as per investigator judgement
21. Individuals who, in the opinion of the investigator, are considered to be incompliant clinical attendees or unlikely for any reason to be able to complete the trial as required
22. Clinically relevant deviation of screening laboratory parameters at V1
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Analyze & Realize
NETWORK
The Archer-Daniels-Midland Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
analyze & realize GmbH
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTB2022TN103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.